Nautilus Biotechnology (NAUT) vs Sutro Biopharma (STRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Nautilus Biotechnology (NAUT) has outperformed Sutro Biopharma (STRO) over the past year, gaining 126.3% versus a gain of 74.5%. Over five years, NAUT leads with a -65.7% price change compared with -92.3% for STRO. Sutro Biopharma is the larger company by market cap ($260.7 million vs $225.9 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NAUT | STRO |
|---|---|---|
| Share price | $1.78 | $15.72 |
| Market cap | $225.88M | $260.66M |
| 1-day change | -9.44% | +7.23% |
| YTD return | +0.51% | +26.71% |
| 1-year return | +126.33% | +74.52% |
| 5-year return | -65.67% | -92.28% |
| EPS (TTM) | $-0.45 | $-17.28 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.31 | $43.85 |
| 52-week low | $0.82 | $7.15 |
| Distance from 52-week high | -58.82% | -64.15% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +115.77% | +200.45% |
| Average volume | 2.59M | 286.74K |
| Shares outstanding | 127.26M | 16.58M |
| Employees | 127 | 128 |
| Sector | Industrials | Health Care |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NAUT has outperformed STRO by 51.8 percentage points over the past year.
- The two companies sit in different sectors: Nautilus Biotechnology in Industrials and Sutro Biopharma in Health Care.
About Nautilus Biotechnology
NAUT stock →Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis.
Industrials · Biotechnology: Laboratory Analytical Instruments · 127 employees
About Sutro Biopharma
STRO stock →Sutro Biopharma, Inc. operates as an oncology company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 128 employees
NAUT vs STRO FAQ
Which is bigger, Nautilus Biotechnology or Sutro Biopharma?
Sutro Biopharma (STRO) is larger, with a market capitalization of $260.66M compared with $225.88M for Nautilus Biotechnology (NAUT).
Which stock has performed better over the past year, NAUT or STRO?
NAUT returned +126.33% over the past 12 months, compared with +74.52% for STRO (price return, excluding dividends). Past performance does not predict future results.
Are Nautilus Biotechnology and Sutro Biopharma in the same industry?
No. Nautilus Biotechnology is in the Industrials sector, while Sutro Biopharma is in Health Care.